PCPC Statement on FDA’s Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
April 11, 2025
FOR IMMEDIATE RELEASE
CONTACTS:
Tesia Williams (202) 297-1232 [email protected]
Team [email protected]
PCPC Statement on FDA’s Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
WASHINGTON, D.C. — Personal Care Products Council (PCPC) appreciates the U.S. Food and Drug Administration’s (FDA) recent announcement that it will phase out animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods. We agree with the FDA that continued reliance on outdated animal testing models is unnecessary and inefficient, and we urge FDA to extend this ban to cosmetics and over-the-counter (OTC) drugs, such as sunscreen products, as well.
PCPC and our member companies have long supported an end to animal testing for cosmetics and personal care products, including OTCs. We are proud to support passage of the Humane Cosmetics Act, and we have long advocated for FDA to adopt a framework based on advanced scientific new approach methodologies. We are encouraged to see positive momentum in this direction and look forward to continued engagement with FDA to advance efficient, innovative and safe methodologies.
###